国信（香港）基金周报 2025 年 7 月 14 日 美对等关税战升级，港股预计受影响有限并冲击新高 一、国信香港精选基金表现 表 1 国信香港精选基金表现 | 资产 类别 | 基金名称 | 收益情况 | 推荐理由 | | --- | --- | --- | --- | | EAT | 华夏精选美元货币基金 | 4.44% | 最新七天年化 - 现金管理工具，产品随时申赎，目前美国基准利率仍然较高 | | 金 米 | 高腾微金美元货币市场基金 | | 最新七天年化 | | | | 4.52% | | | 券 | 泰康开泰海外短期债券基金 | 周涨幅 0.149% | 近一年收益率5.93%,投资于海外发行的投资级短期固收工具,可作为 现金替代和避险配置的核心工具。 | | ਐੱਵ | 10年期美国国债 | 最新收益率 | 最大的债券市场,兼具高流动性和安全性,在美联储意外降息时资本利 | | | | 4.4093% | 得收益更有优势,而现处于美国降息周期 | | | 华夏恒生香港生物科技指数E | 周跌幅 | 指数覆盖港股"科技"与"生物医药"两大核心板块,适合阶段性估值修复布 局,近一年收益率达87.57 ...

成都欧林生物科技股份有限公司 信息披露暂缓与豁免事务管理制度 第一章 总则 第一条 为规范成都欧林生物科技股份有限公司（以下简称"公司"）信息披露暂 缓与豁免行为，督促公司及相关信息披露义务人（以下简称"信息披露义务人"）依法 合规地履行信息披露义务，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司信息披露管理办法》《上市公司信息披露暂缓与豁免管理规定》《上海证券 交易所科创板股票上市规则》(以下简称"《上市规则》")《成都欧林生物科技股份有 限公司章程》（以下简称"《公司章程》"）及其他有关法律、法规的规定，结合公司 实际情况，制定本制度。 第二条 信息披露义务人按照《上市规则》等相关法律法规及规范性文件的规定， 暂缓、豁免披露临时报告，在定期报告、临时报告中豁免披露中国证券监督管理委员会 （以下简称"中国证监会"）和上海证券交易所规定或者要求披露的内容，适用本制度。 第三条 信息披露义务人应当真实、准确、完整、及时、公平地披露信息，不得滥 用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实施内幕交易、操纵市场等 违法行为。 第四条 公司应当审慎确定信息披露暂缓、豁免事项，履行内部审核程 ...

江苏省战略性新兴产业母基金(简称"江苏省战新母基金")第三批产业专项基金正式启动。 截至目前，江苏战新基金集群已经实现全省13个设区市全覆盖，重点投资新能源、新能源(智能网联)汽 车、低空经济和空天产业、新型电力(智能电网)、海工装备与高技术船舶、新材料等产业领域。 此外，江苏省农垦集团发起的规模10亿元的江苏农垦现代生物技术产业投资基金，将围绕医药健康、生 物农业、特色新型食品等相关领域开展直投，进一步加大省属企业战略性新兴产业投资布局，增强国有 企业核心功能、提高核心竞争力。 在扶持天使投资方面，由江苏高投集团和苏州创新投资集团共同发起的5亿元江苏省新智未来产业天使 投资基金，重在支持更多高层次人才创新创业，推动通用智能、先进计算、第三代半导体、量子科技、 合成生物、前沿新材料、深海、深地、空天开发等未来产业领域更多前沿科技成果转化落地，进一步服 务江苏省打造具有全球影响力的产业科技创新中心。 据悉，江苏省战新母基金自去年6月正式启动运作至今刚满一年，该基金充分发挥政府引导基金的撬动 效应，成效显著，有力支撑了全省战略性新兴产业和未来产业的发展壮大：目前两批产业专项基金共36 只、规模914亿元已全部组建 ...

科创板"考生"武汉禾元生物科技股份有限公司（以下简称"禾元生物"）成功过会，距上市仅一步之遥。 这家专注重组蛋白技术的公司，在历经财务资料过期中止等波折后，于今年7月叩响科创板大门，并于7 月4日正式提交注册申请。 募资24亿元，相较于此前募资规模大幅缩水 | 序号 | | | 拟投入募集 | | 早见: 门 元 | | --- | --- | --- | --- | --- | --- | | | 项目名称 | 投资总额 | 资金 | 项目备案批文 | 环评批复 | | | 重组人自蛋白产业化基 | | | 2405-420118- | 武新环管 | | | 地建设项目 | 190,866.57 | 165,752.73 | 04-01-170733 | [2024]2号 | | 7 | 新药研发项目 | 79,369.00 | 64,247.27 | 不适用 | 不适用 | | 3 | 补充流动资金 | 10,000.00 | 10,000.00 | 不适用 | 不适用 | | | 合计 | 280,235.57 | 240,000.00 | | | 来源于禾元生物招股书 显然，重组人白蛋白产业化基地建设 ...

近日，据天眼查显示，湖北长江一号健康产业投资合伙企业（有限合伙）成立，执行事务合伙人为湖北 省长江新动能私募基金管理有限公司，出资额34.01亿人民币。合伙人信息显示，该基金由湖北长江产 业投资基金有限公司（份额99.97%）、湖北省长江新动能私募基金管理有限公司（份额0.03%）共同出 资。这两家公司均隶属于长江产业集团，是湖北省重要的国有资本投资平台。 （经济观察网 李强/文） 中研普华调研数据显示，截至2024年底，湖北省大健康领域高新技术企业数量突破1500家，较2020年增 长65%。在化学制药方面，人福医药（600079）、远大医药等企业在全国麻醉镇痛药、眼药水等细分市 场占据领先地位；在生物制药领域，武汉光谷生物城聚集了超过400家生物企业，在基因工程、疫苗研 发等领域形成了区域集群优势。 此外，根据在7月初长江产业集团召开"生物医药和大健康产业突破性发展"专题研讨会的有关消息，长 江一号健康产业投资基金也将承担组建长江产业集团生物医药与大健康产业专家委员会，依托专家力 量，深入研判行业动态、技术路线、并购标准等，为项目推进提供智力支持，提升产业发展的科学性和 前瞻性。 资料显示，长江产业集团成 ...

Market Overview - The Shanghai Composite Index closed at 3519.65 points, up 0.27%, with a trading volume of 623.1 billion yuan [1] - The Shenzhen Component Index closed at 10684.52 points, down 0.11%, with a trading volume of 835.6 billion yuan [1] - The ChiNext Index closed at 2197.07 points, down 0.45%, with a trading volume of 387.28 billion yuan [1] - The STAR Market 50 Index closed at 992.39 points, down 0.21%, with a trading volume of 22.92 billion yuan [1] - Total trading volume for both markets was 1458.75 billion yuan, a decrease of 253.38 billion yuan from the previous trading day [1] Sector Performance - Strong sectors included machinery, public utilities, oil and petrochemicals, textiles, chemicals, non-ferrous metals, and pharmaceuticals [2] - Active concepts included PEEK materials, humanoid robots, geothermal energy, and innovative drugs [2] - Weak sectors included real estate, media, securities, education, insurance, and retail [2] Fund Flow - The net outflow of main funds from the Shanghai and Shenzhen markets was 26.576 billion yuan [3] - The net outflow from the ChiNext was 12.112 billion yuan, and from the CSI 300 was 6.366 billion yuan [4] - Only four sectors saw net inflows: machinery (394 million yuan), home appliances (117 million yuan), coal (38 million yuan), and oil and petrochemicals (37 million yuan) [4] Individual Stock Performance - A total of 2089 stocks saw net inflows, with 37 stocks receiving over 100 million yuan in net inflows [5] - The stock with the highest net inflow was Zhongji Xuchuang, with 497 million yuan [6] - Conversely, 3048 stocks experienced net outflows, with 92 stocks seeing over 100 million yuan in net outflows [7] - BYD had the highest net outflow at 1.308 billion yuan [8] Institutional Activity - Institutions had a net buy of approximately 33.89 million yuan, with 17 stocks being net bought and 14 stocks net sold [9] - The stock with the highest institutional net buy was Xiangyang Bearing, with about 111 million yuan [10]

就在这个看似平常的周末，资本市场却悄然翻过重要一页。 7月13日，上交所正式发布了《科创板上市公司自律监管指引第5号——科创成长层》，距离证监会主席在陆家嘴论坛提 出"1+6"政策矩阵还不到一个月时间。 ——前沿创新者的"成长摇篮" 要理解科创成长层的核心价值，首先需要明确其定位。 科创成长层本质上是一个为未盈利优质科技企业量身打造的"成长摇篮"，它精准定位那些正处于研发攻坚期、尚未实现盈 利但具备高成长潜力的科技企业。 | 政策 | 关键突破 | 解决痛点 | | --- | --- | --- | | 重启第五套上市标准 | 未盈利企业市值门槛40亿,覆盖芯片/AI/低空经济 | 打破生物医药独占，助力芯片企业上市 | | 专业机构投资者定价试点 | PE/VC参与未盈利企业估值，结果供审核参考 | 提升定价专业性,减少散户风险 | | IPO预先审阅(秘密递交) | 非公开提交材料，审核通过后快速上市 | 保护商业机密,缩短IPO周期 | | 在审企业定向增资 | IPO排队期间可向老股东融资 | 避免研发资金链断裂 | | 再融资与战投认定优化 | 简化再融资流程，战投认定放宽至产业链协同机构 | 支 ...

文 |《瞭望》新闻周刊记者 刘巍巍 "实验室允许以高成本产出'概念件'，在量产阶段，怎么以更低成本、更高效率生产出高合格率、高可 靠性的产品，至关重要。" "在这里，创业成本降到最低，我们只需要专注创新研发。""我们不需要在初期增加辅助人员，也不需 要扩建场地，企业的运营成本从千万级降至百万级。" 生物医药研发是"九死一生"的事。业内普遍认为，从前期研究到临床试验，最终获批上市，只有一成左 右的药物可以幸存下来。这个过程，往往持续10年甚至更长时间，耗费巨大的人力物力。 助力生物医药创新穿越"死亡之谷"，生物医药中试平台在提升科技成果转化率、加快研发进度、降低创 业成本等方面发挥越来越显著的作用。 今年5月，工业和信息化部首批重点培育中试平台初步名单公示，其中药品33家、医疗器械7家，约占总 数的1/6。 生物医药中试需要解决从实验室到中试的工艺不确定性以及安全风险不确定性等，产业转化风险大与经 济价值突出并存，随着基因治疗、细胞药物等前沿技术发展，复杂性将进一步提升。 业内人士及专家表示，需聚焦关键共性问题，加大跨学科协同，加大投入和培育力度，推动中试平台加 速发展，为生物医药创新成果产业化应用提供有力支撑 ...

Group 1 - Aerospace Science and Technology expects a net profit of 68 million to 95 million yuan for the first half of 2025, representing a growth of 1628.83% to 2315.27% compared to the same period last year [1] - Huaxia Airlines anticipates a net profit of 220 million to 290 million yuan for the first half of 2025, an increase of 741.26% to 1008.93% year-on-year [1] - Shida Group forecasts a net loss of 44 million to 65 million yuan for the first half of 2025, marking a shift from profit to loss [1] Group 2 - Jiaao Environmental Protection expects a net loss of 70 million to 90 million yuan for the first half of 2025 [3] - Haima Automobile predicts a net loss of 60 million to 90 million yuan for the first half of 2025, compared to a loss of 152 million yuan in the same period last year [3] - Huaibei Mining anticipates a net profit of approximately 1.027 billion yuan for the first half of 2025, a decrease of about 65% year-on-year [3] Group 3 - Quanfu Automobile expects a net loss of 155 million to 185 million yuan for the first half of 2025 [5] - Gaode Infrared signed a procurement agreement worth 879 million yuan, which is expected to positively impact its operating performance for the year [5] - Zhongchen Co. won a project from Southern Power Grid worth 379 million yuan, representing 12.26% of its audited revenue for 2024 [5] Group 4 - Daheng Technology anticipates a net loss of 406,000 yuan for the first half of 2025, compared to a loss of 988,250 yuan in the same period last year [6] - Dazhongnan expects a net profit of 6.5 million to 8 million yuan for the first half of 2025, a recovery from a loss of 15.325 million yuan last year [6] - Xianfeng Holdings projects a net profit of 34 million to 42 million yuan for the first half of 2025, a year-on-year increase of 524.58% to 671.53% [7] Group 5 - Shuangxiang Co. expects a net profit of 115 million to 150 million yuan for the first half of 2025, a growth of 128.1% to 197.53% year-on-year [8] - ST Xintong anticipates a net loss of 67 million to 97 million yuan for the first half of 2025 [9] - Jishi Media forecasts a net loss of 187 million to 233 million yuan for the first half of 2025 [10] Group 6 - Suli Co. expects a net profit of 72 million to 86 million yuan for the first half of 2025, a year-on-year increase of 1008.39% to 1223.91% [11] - Wanli Co. anticipates a net loss of 19 million yuan for the first half of 2025, compared to a loss of 12.9238 million yuan last year [12] - Langzi Co. projects a net profit of 22 million to 26 million yuan for the first half of 2025, an increase of 31.74% to 55.69% year-on-year [14] Group 7 - Changjiang Securities expects a net profit of 1.652 billion to 1.81 billion yuan for the first half of 2025, a growth of 110% to 130% [15] - Huahong Technology anticipates a net profit of 70 million to 85 million yuan for the first half of 2025, a year-on-year increase of 3047.48% to 3721.94% [16] - Chenhua Co. plans to invest 30 million yuan in financial products with an expected annual yield of 3.20% [16] Group 8 - Zijing Mining expects a net profit of approximately 23.2 billion yuan for the first half of 2025, a growth of about 54% year-on-year [28] - Limin Co. anticipates a net profit of 26 million to 28 million yuan for the first half of 2025, a year-on-year increase of 719.25% to 782.27% [29] - Huazhong Securities expects a net profit of 1.035 billion yuan for the first half of 2025, a growth of 44.94% year-on-year [30]

Group 1 - The average stock price of the Sci-Tech Innovation Board is 30.97 yuan, with 42 stocks priced over 100 yuan, and the highest priced stock is Cambricon at 565.06 yuan [1][2] - Among the stocks priced over 100 yuan, 358 stocks increased in price today, while 219 stocks decreased [1] - The average premium of the stocks priced over 100 yuan relative to their issue price is 325.52%, with the highest premiums from Anji Technology, Baile Tianheng, and Hotgen Biotech at 1085.87%, 1049.31%, and 877.90% respectively [1][2] Group 2 - The net outflow of main funds from the stocks priced over 100 yuan today is 1.58 billion yuan, with significant inflows into Cambricon, Stone Technology, and Anji Technology [2] - The total margin balance for stocks priced over 100 yuan is 25.863 billion yuan, with the highest margin balances held by Haiguang Information, Cambricon, and Zhongwei Company [2] - The stocks priced over 100 yuan are concentrated in the electronics, pharmaceutical, and computer industries, with 20, 8, and 6 stocks respectively [1][2]